Bracelets TRIZ Cases Forum

WCLC 2026 delivered a concentrated test of where thoracic oncology is genuinely advancing-and where the evidence is still too early to change practice. Across targeted therapy, antibody-drug conjugates (ADCs), immunotherapy and surveillance strategies, the most important question was not simply whether a study was “positive.” It was whether the result was mature, clinically interpretable and strong enough to alter the next treatment decision. The WCLC 2026 Plenary Studies Clinical Evidence Review examines nine high-interest studies across SCLC and NSCLC. Click the image to access the report. Free clinical evidence review Nine studies. One evidence framework. Fewer misleading comparisons. Download the full WCLC 2026 review for study-level evidence tables, trial design, efficacy and safety context, evidence limitations and the questions that still need answers. Download the WCLC 2026 report -> Why WCLC 2026 matters for lung cancer R&D The IASLC 2026 World Conference on Lung Cancer , held in Seoul from September 12-15, brought together practice-defining updates and emerging data across thoracic malignancies. The report reviewed here focuses on nine plenary-anchored studies: MAVERICK, YL201 (Tam-Peli), ARTEMIS-008, EVOKE-03/KEYNOTE-D46, ADAURA, PAPILLON, REZILIENT3, ARROS-1 and DESTINY-Lung04 . Taken together, they describe a field moving in three directions at once: Earlier and more precise intervention , illustrated by adjuvant osimertinib and first-line biomarker-selected regi

ESC Congress 2026 did not deliver a simple parade of “winners” and “losers.” It delivered something more useful: a test of how carefully clinicians, medical-affairs teams and biopharma strategists interpret evidence when endpoints diverge, subgroup signals attract attention and operational outcomes refuse to move. Across seven pivotal Hot Line and late-breaking studies, only two produced clearly positive primary results. Four had neutral primary comparisons. One produced a split verdict—cardiovascular benefit without improvement in a broader healthy-aging endpoint. Together, the studies show why a headline is never a substitute for reading the endpoint definition, effect size, confidence interval, comparator and safety context. The ESC Congress 2026 Clinical Evidence Review brings seven pivotal trials, guideline developments and emerging AI findings into one decision-oriented report. The new ESC Congress 2026 Clinical Evidence Review brings those layers together in one concise, decision-oriented report. It reviews seven major trials, separates confirmatory findings from exploratory signals, and adds context on guidelines and emerging AI applications in cardiovascular care. New clinical evidence report Move beyond the headlines from ESC Congress 2026 Explore seven pivotal trials, endpoint-level evidence, safety signals, guideline developments and emerging cardiovascular AI applications. Download the Full Report → ESC Congress 2026 at a glance Evidence signal What the review fo

PRMT5 was featured at WCLC 2026 as a novel therapeutic target in lung cancer, particularly in tumours with co-occurring mutations. Presented in WCLC 2026 abstracts, sessions explored the role of PRMT5 in epigenetic regulation, the rationale for PRMT5 inhibition in specific molecular contexts including MTAP deletion, and early clinical data. The congress highlighted PRMT5 as an emerging target in the precision medicine landscape, with synthetic lethal approaches offering the potential for targeted therapy in molecularly defined lung cancer populations with specific co-mutation patterns. This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS , which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary PRMT5 is a molecular target in NSCLC defined by MTAP-selective MTA-cooperative PRMT5 inhibitors (AMG 193, MRTX1719, TNG908, TNG462) and MAT2A inhibitors (IDE397) exploiting synthetic lethality in MTAP-deleted tumors including NSCLC. At WCLC 2026, sessions examined therapeutic approaches directed at this target, spanning small-molecule inhibitors, antibodies, ADCs, and combination regimens depending on biology. Data covered approved therapies and next-generation candidates. Notably, the target attracts multiple modalities and sponsors, and competitive differentiation depends on target selectivity, resistance profile, and combination potential. Recent patent activity signals cont

BRAF V600E was discussed at WCLC 2026 abstracts in sessions exploring rare oncogenic drivers in NSCLC. Featured in abstracts, sessions examined the role of BRAF and MEK inhibitor combinations, the clinical characteristics of BRAF-mutant NSCLC, and the importance of molecular testing. The congress reinforced BRAF V600E as an actionable target in lung cancer, with targeted therapy combinations offering significant clinical benefit, and emphasised the need for comprehensive genomic profiling to identify patients with this and other rare actionable alterations who may benefit from personalised therapy. This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS , which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary BRAF V600E is a molecular target in NSCLC defined by actionable BRAF V600E mutation in NSCLC addressed by BRAF plus MEK inhibitor combinations across metastatic and perioperative settings. At WCLC 2026, sessions examined therapeutic approaches directed at this target, spanning small-molecule inhibitors, antibodies, ADCs, and combination regimens depending on biology. Data covered approved therapies and next-generation candidates. Notably, the target attracts multiple modalities and sponsors, and competitive differentiation depends on target selectivity, resistance profile, and combination potential. Recent patent activity signals continued innovation across constru

TP53 was discussed at WCLC 2026 late-breaking abstracts as the most commonly mutated gene in lung cancer and a determinant of therapeutic response. Featured in WCLC 2026 abstracts, sessions explored the role of TP53 mutations in tumour biology, their association with other oncogenic drivers, and their impact on response to chemotherapy, immunotherapy, and targeted therapy. The congress addressed the challenges of targeting TP53 directly, the potential for synthetic lethal approaches, and the importance of TP53 as a co-mutation in understanding and predicting therapeutic outcomes in molecularly defined lung cancer. This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS , which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary TP53 is a molecular target in NSCLC defined by synthetic lethal approaches (ATR, WEE1, MDM2 modulation) and selective TP53 mutant reactivators (rezatapopt for Y220C) targeting the most commonly mutated tumor suppressor gene in lung cancer. At WCLC 2026, sessions examined therapeutic approaches directed at this target, spanning small-molecule inhibitors, antibodies, ADCs, and combination regimens depending on biology. Data covered approved therapies and next-generation candidates. Notably, the target attracts multiple modalities and sponsors, and competitive differentiation depends on target selectivity, resistance profile, and combination potential.

CDCP1 was featured at WCLC 2026 oral presentations as a novel therapeutic target in lung cancer. Presented in WCLC 2026 abstracts, early research explored CDCP1 expression in NSCLC, its role in tumour progression and metastasis, and the potential for targeted therapy including antibody-drug conjugates. The congress highlighted the ongoing discovery of novel therapeutic targets in lung cancer, with CDCP1 representing one of several emerging tumour-associated antigens under investigation as potential ADC targets for molecularly defined or broadly expressed lung cancer populations. This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS , which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary CDCP1 is a molecular target in NSCLC defined by early-stage antibody-drug conjugate and monoclonal antibody discovery programs directed at CUB domain-containing protein 1 (CDCP1) in NSCLC and other solid tumors. At WCLC 2026, sessions examined therapeutic approaches directed at this target, spanning small-molecule inhibitors, antibodies, ADCs, and combination regimens depending on biology. Data covered approved therapies and next-generation candidates. Notably, the target attracts multiple modalities and sponsors, and competitive differentiation depends on target selectivity, resistance profile, and combination potential. Recent patent activity signals continued innovation across cons

CTLA-4 was discussed at WCLC 2026 Seoul in the context of dual immune checkpoint blockade with nivolumab and ipilimumab. Featured in WCLC 2026 oral presentations, sessions explored the role of CTLA-4 blockade in combination with PD-1 inhibition for advanced NSCLC, the toxicity profile of dual checkpoint blockade, and patient selection criteria. The congress addressed the ongoing role of CTLA-4 as a therapeutic target in lung cancer, with combination approaches aiming to enhance antitumour immunity while managing the increased toxicity associated with dual immune checkpoint blockade. This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS , which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary CTLA-4 is a molecular target in NSCLC defined by anti-CTLA-4 monoclonal antibodies (ipilimumab, tremelimumab), Fc-enhanced anti-CTLA-4 (botensilimab), and PD-1 x CTLA-4 bispecific antibodies (volrustomig, cadonilimab) combined with anti-PD-1 or PD-L1 for enhanced antitumor immunity. At WCLC 2026, sessions examined therapeutic approaches directed at this target, spanning small-molecule inhibitors, antibodies, ADCs, and combination regimens depending on biology. Data covered approved therapies and next-generation candidates. Notably, the target attracts multiple modalities and sponsors, and competitive differentiation depends on target selectivity, resistance profile, and combinatio

ROS1 was featured at WCLC 2026 , with lorlatinib, entrectinib, and taletrectinib discussed in WCLC 2026 oral presentations and abstracts. Sessions explored ROS1 fusion variants, the TKI treatment sequence, CNS activity, resistance mechanisms including G2032R mutations, and the role of next-generation agents. The congress reinforced the importance of ROS1 testing in advanced NSCLC and the growing therapeutic options for ROS1-rearranged lung cancer, with optimal TKI selection and sequencing remaining key clinical considerations to maximise long-term disease control. This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS , which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary ROS1 is a molecular target in NSCLC defined by first-generation and next-generation ROS1 tyrosine kinase inhibitors (crizotinib, entrectinib, lorlatinib, repotrectinib, taletrectinib, zidesamtinib) addressing ROS1 fusions and G2032R resistance in NSCLC. At WCLC 2026, sessions examined therapeutic approaches directed at this target, spanning small-molecule inhibitors, antibodies, ADCs, and combination regimens depending on biology. Data covered approved therapies and next-generation candidates. Notably, the target attracts multiple modalities and sponsors, and competitive differentiation depends on target selectivity, resistance profile, and combination potential. Recent patent activity signals conti

TROP2 (TACSTD2) was extensively discussed at WCLC 2026 abstracts, with multiple TROP2-directed ADCs including sacituzumab govitecan, tam-peli, and sacituzumab tirumotecan featured in WCLC 2026 oral presentations and abstracts. Sessions explored TROP2 expression in lung cancer, the rationale for TROP2-targeted therapy, and the evolving landscape of TROP2 ADCs with different payloads and linkers. The congress reinforced TROP2 as a validated ADC target in NSCLC, with multiple agents competing and combination strategies with immunotherapy under active investigation. This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS , which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary TROP2 (TACSTD2) is a molecular target in NSCLC defined by TROP2-directed antibody-drug conjugates and peptide-drug conjugates with SN-38, DXd, belotecan-analog, and MMAE payloads across NSCLC, TNBC, urothelial, and other TROP2-expressing tumors. At WCLC 2026, sessions examined therapeutic approaches directed at this target, spanning small-molecule inhibitors, antibodies, ADCs, and combination regimens depending on biology. Data covered approved therapies and next-generation candidates. Notably, the target attracts multiple modalities and sponsors, and competitive differentiation depends on target selectivity, resistance profile, and combination potential. Recent patent activity signals continued innov

EGFR-TKI-resistant NSCLC was a major focus at WCLC 2026 highlights, with discussions of resistance mechanisms and novel therapeutic strategies featured in WCLC 2026 oral presentations and abstracts. Sessions explored tertiary EGFR mutations, MET amplification, histologic transformation, and the role of next-generation EGFR inhibitors, combination therapies, and ADCs. The congress addressed the critical unmet need for effective therapies after progression on EGFR TKIs, the importance of repeat molecular testing at resistance, and the growing pipeline of novel agents designed to overcome acquired resistance mechanisms. This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS , which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary EGFR TKI-Resistant NSCLC is a lung cancer subtype defined by resistance mechanisms including MET amplification, HER3 upregulation, and histologic transformation addressed by EGFR/MET bispecific antibody amivantamab, TROP2 and HER3 antibody-drug conjugates, MET TKIs, and EGFR/HER3 bispecific ADCs. At WCLC 2026, sessions covered current standards of care, emerging therapies, and unmet needs for this disease. Data spanned multiple therapeutic classes and treatment settings. Notably, the disease presents distinct clinical challenges that shape competitive priorities across sponsors. Multiple therapeutic classes address different aspects of the diseas